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ORIGINAL ARTICLE
MiR-29b replacement inhibits proteasomes and disrupts
aggresome+autophagosome formation to enhance the
antimyeloma beneﬁt of bortezomib
S Jagannathan1,2, N Vad1,2, S Vallabhapurapu3, S Vallabhapurapu3, KC Anderson4 and JJ Driscoll1,2,3
Evading apoptosis is a cancer hallmark that remains a serious obstacle in current treatment approaches. Although proteasome
inhibitors (PIs) have transformed management of multiple myeloma (MM), drug resistance emerges through induction of the
aggresome+autophagy pathway as a compensatory protein clearance mechanism. Genome-wide proﬁling identiﬁed microRNAs
(miRs) differentially expressed in bortezomib-resistant myeloma cells compared with drug-naive cells. The effect of individual miRs
on proteasomal degradation of short-lived ﬂuorescent reporter proteins was then determined in live cells. MiR-29b was signiﬁcantly
reduced in bortezomib-resistant cells as well as in cells resistant to second-generation PIs carﬁlzomib and ixazomib. Luciferase
reporter assays demonstrated that miR-29b targeted PSME4 that encodes the proteasome activator PA200. Synthetically
engineered miR-29b replacements impaired the growth of myeloma cells, patient tumor cells and xenotransplants. MiR-29b
replacements also decreased PA200 association with proteasomes, reduced the proteasome’s peptidase activity and inhibited
ornithine decarboxylase turnover, a proteasome substrate degraded through ubiquitin-independent mechanisms. Immunoﬂuorescence
studies revealed that miR-29b replacements enhanced the bortezomib-induced accumulation of ubiquitinated proteins but did not
reveal aggresome or autophagosome formation. Taken together, our study identiﬁes miR-29b replacements as the ﬁrst-in-class
miR-based PIs that also disrupt the autophagy pathway and highlight their potential to synergistically enhance the antimyeloma
effect of bortezomib.
Leukemia (2015) 29, 727–738; doi:10.1038/leu.2014.279
INTRODUCTION
MicroRNAs (miRs) are noncoding RNAs that control gene
expression and are deregulated in many human cancers.1,2
Alteration in miR expression is linked to tumorigenesis and
expression proﬁling has identiﬁed miR signatures associated with
cancer diagnosis, staging and therapeutic response.3 Loss of a
tumor-suppressive miR activates inherently oncogenic pathways
to promote cancer phenotypes and drug resistance.4,5 The
rationale to develop miR therapeutics is based upon the premise
that aberrantly expressed miRs have key roles in cancer and that
correcting these deﬁciencies by restoring miR function may
provide therapeutic beneﬁt.6
The ubiquitin (Ub)+proteasome system (UPS) maintains pro-
teotasis by degrading misfolded and short-lived proteins.7 The
proteasome is the catalytic core of the UPS, and pharmacologic
inhibition of the proteasome induces cancer cell death.8 Protea-
some inhibitors (PIs) have been exploited for therapeutic gain to
treat multiple myeloma (MM) and yield durable responses that
enhance survival.9,10 Bortezomib (Velcade, Millennium-Takeda
Oncology, Cambridge, MA, USA) has emerged as the standard-
of-care for MM but serious obstacles remain.11 Many patients do
not respond to PIs; those who do respond inevitably develop
resistance and the molecular bases of patient susceptibility
remains unknown.12–14 Moreover, next-generation PIs possess
their own adverse effects and are unlikely to provide long-term
beneﬁt without the development of drug resistance.
Drug resistance still accounts for the majority of tumor relapses
and cancer-related deaths. Whereas bortezomib promotes the
accumulation of polyubiquitinated proteins, it also induces
aggresome and autophagosome formation to promote protein
clearance, tumor survival and relative drug resistance. Pharmaco-
logic inhibition of both proteasomes and autophagy offers great
potential to overcome therapeutic resistance. Here, we demon-
strate that miR-29b represses PSME4 to inhibit proteasomes but, in
contrast to bortezomib, does not induce aggresome or autopha-
gosome formation. Hence, miRs may offer a therapeutic advan-
tage for myeloma treatment by inhibiting proteasomes without
inducing pro-survival autophagy.
MATERIALS AND METHODS
Cells and reagents
MM cell lines were grown in complete RPMI and AMCL1, AMCL2 and
Waldenström’s macroglobulinemia cells (Massachusett’s General Hospital,
Boston, MA, USA) in complete DMEM. Bortezomib, carﬁlzomib and ixazomib
were from Selleck Chemicals (Houston, TX, USA), succinyl-Leu-Leu-Val-Tyr-
MCA (Suc-LLVY-MCA) and XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophe-
nyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium) (Sigma, St Louis, MO, USA)
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and miR replacements/antagomirs (Switchgear Genomics, Menlo Park,
CA, USA).
Live-cell measurement of proteasome activity
The short-lived ﬂuorescent reporter GFPu was constructed by fusing a 16-
amino-acid degradation signal to green-ﬂuorescent protein (GFP)15
(Clontech, Mountain View, CA, USA). Human embryonic kidney cells were
stably transfected with GFPu.
MiR replacements/antagomir transfection
Replacements/antagomirs were transfected into target cells using Lipo-
fectamine RNAimax (Invitrogen, Carlsbad, CA, USA). MiRs were diluted in
Opti-MEM, mixed with RNAimax and added dropwise.
Transduction of miR-expressing lentivirus
Lentivirus vectors (SBI Biosystems, Mountain View, CA, USA) that expressed
scrambled or experimental miRs were transfected with packaging vector,
pPACKH, into 293T cells using Lipofectamine 2000 (Invitrogen). After 48 h,
the virus was collected and RPMI8226 cells transduced with vectors
expressing scrambled miR, miR-29b or miR-29b. Those lacking the nuclear
localization signal (NLS) were designated miR-29bΔNLS. Cells were mixed
with virus and polybrene (8 μg/ml), centrifuged at 2000 r.p.m. for 90min,
incubated overnight, media changed and selected in puromycin.
Viability assay
Cells (200 μl) were plated, transfected with miRs, incubated for 72 h and
activated XTT was added. Absorbance was determined using a BMG
Labtech OPTIMA plate reader (BMG Labtech Inc., Cary, NC, USA).
Quantitation of ﬂuorescence
Cells were transfected with miRs and incubated for 48 h. Bortezomib was
added, cells were incubated for 16 h and visualized using a Zeiss LSM 170
confocal microscope with Axio Observer Z1 (Zeiss Microscopy, Jena,
Germany). Fluorescence was quantiﬁed using ImageJ (NIH, Bethesda, MD,
USA) and normalized relative to vehicle-treated cells.
Nuclear factor-kappaB (NFκ-B) activity
Cells were transduced with plasmids expressing G-Luc under NFκ–B,
cytomegalovirus or SV40 promoter control. Cells were then transfected
with control or experimental miRs (20 nM), grown for 24 h, split into equal
portions and one-half was treated with 10 ng/ml tumor necrosis factor-α
(TNF-α). Cells were incubated for 16 h and luminescence determined from
the media using BMG Labtech FLUOstar OPTIMA after the addition of Gar2
reagent and 1× supplement.16,17
Proliferation assay
The miR effect on proliferation was determined using the 5-bromo-2′-
deoxyuridine (BrdU) kit (Cell Signaling Technology, Danvers, MA, USA) to
detect incorporation of BrdU into the newly synthesized DNA. RPMI8226
cells were labeled using BrdU-containing media, ﬁxed, DNA denatured and
mouse anti-BrdU monoclonal antibody was added. Anti-mouse IgG
horseradish peroxidase (HRP)-linked antibody detected bound anti-BrdU
ab. The HRP substrate TMB (3,30 ,5,50-tetramethylbenzidine) was added as a
color developer and absorbance was proportional to the incorporated
BrdU and proliferation.
Methylcellulose colony formation assay
Cells transduced with miR-expressing lentiviral vectors were plated in
1.27% methylcellulose. After 9 days, colonies were counted using a Nikon
(Nikon Inc., Melville, NY, USA) eclipse TE200 bright ﬁeld microscope.
Colonies with o10 cells were excluded.
Apoptosis assay
Cells were transfected with miRs, incubated for indicated times at 37 °C
and 5% CO2. Cells were then collected and centrifuged at 200 g for 5 min.
The supernatant was discarded and the pellet was washed with 1 × buffer.
Cells were then resuspended in 90 μl of 1 × buffer and 10 μl of ﬂuorescein
isothiocyanate-conjugated annexin V (Molecular Probes, Grand Island, NY,
USA), incubated in the dark and analyzed using a Coulter epics XL-MCL
(Beckman-Coulter Inc., Brea, CA, USA).
Real-time (RT) measurements
Longitudinal analysis of cell conﬂuency was determined using the Incucyte
Zoom second-generation live-cell kinetic imaging system and software
(Essen Bioscience, Ann Arbor, MI, USA) integrated with a cell culture
incubator. RPMI8226 cells were transduced with miR, incubated for 48 h,
bortezomib added and images acquired every 2 h over 48 h. Conﬂuence
and cells/mm2 were quantiﬁed.
Western blot
In all, 1 × 106 cells were placed in six-well plates and transfected with
scrambled control or experimental miRs. Cells were collected, centrifuged
at 200 g for 8 min, the supernatant discarded and the pellet washed with
1× phosphate-buffered saline (PBS). The pellet was resuspended in RIPA
buffer, lysed and centrifuged at 12 000 g for 10 min. Protein concentration
of the lysate was determined using the Pierce BCA Protein Assay Kit
(Thermo-Scientiﬁc, Florence, KY, USA). Samples (20 μg) were electrophor-
esed on 5–20% gels (Wako Chemicals, Richmond, VA, USA) in the XCell
mini-cell system (Invitrogen). Proteins were transferred to nitrocellulose
and incubated with Odyssey (LI-COR, Lincoln, NE, USA) blocking buffer for
30min followed by 1° antibodies (1:1000) for 16 h at 4 °C. Membranes were
washed thrice in PBS-Tween-20 (PBS-T, 0.05%), incubated for 30min with
IR Dye 2° antibody (1:5000) and visualized using the Odyssey infrared
imaging system.
Subcellular fractionation
293T cells were transfected with control or miR replacements, lysates were
prepared and nuclear and cytoplasmic fractions were separated
(Invitrogen).
Generation of PI-resistant cell lines
RPMI8226 cells were grown under standard conditions and exposed to
successively increased concentrations of the PIs bortezomib, carﬁlzomib or
ixazomib over 6 months to generate PI-resistant cells. As controls, parental
cells were exposed to dimethylsulphoxide vehicle under the same
algorithm as resistant cells.
Nondenaturing gel electrophoresis
RPMI8226 cells were transfected with scrambled miR, miR-29b or
miR-29bΔNLS replacements and incubated +/− bortezomib. Gels were
incubated in 25mM Tris–HCl (pH 7.4) 3 mM ATP, 5 mM MgCl2 and Suc-LLVY-
MCA at 37 °C, and free AMC (7-amino-4-methylcoumarin) was visualized
using a UV transilluminator.
RESULTS
Whereas the therapeutic beneﬁt of bortezomib remains
unchallenged, acquired drug resistance remains a major
obstacle toward achieving sustained clinical responses. As the
molecular basis of PI resistance remains poorly deﬁned, we
exposed drug-sensitive myeloma cells to successively increased
concentrations of bortezomib to generate drug-resistant cells
that displayed IC50 values more than ﬁvefold greater than that
determined for parental cells (Supplementary Figure 1). We
then identiﬁed miRs differentially expressed in the bortezomib-
resistant cells. Over 415 000 pre-miR and mature miR were
screened; however, only 26 human miRs were expressed with
statistical difference between bortezomib-resistant and parental
cells (Supplementary Table 1). MiR-17–92 displayed the greatest
increase in expression in bortezomib-resistant cells, whereas
miR-29 family members miR-92-1, miR-21 and miR27 were
signiﬁcantly reduced relative to parental cells and have been
linked to tumorigenesis.18,19 To investigate the biological effect
of miRs differentially expressed in bortezomib-resistant cells,
miR replacements were synthetically engineered to mimic
those miRs increased in bortezomib-resistant cells and synthetic
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antagomirs were designed by base-pair complementarity
to inhibit those miRs reduced in bortezomib-resistant
cells. Replacements or antagomirs were transfected into
myeloma cells and the effect on viability was determined
(Figures 1a and b). Twelve miR replacements and ﬁve
antagomirs increased myeloma viability in a dose-dependent
manner. MiR replacements 1290, 762, 923, 2861, 1246, 638 and
4271 and antagomirs of miRs 29b, 29c, 192 and 27a also
Figure 1. Identiﬁcation of miRs that control UPS activity. (a) MiR replacement effect on viability. Cells were transfected with replacements at
and viability determined using the XTT assay. Shown is the average of triplicate measurements. (b) Antagomir effect on viability. (c) MiR
replacement effect on viability in the presence of bortezomib. Cells were transfected with replacements at indicated concentrations, cultured
for 48 h and then treated with bortezomib at indicated concentrations. (d) Antagomir effect on viability in the presence of bortezomib. Cells
were transfected with antagomirs at indicated concentrations, cultured for 48 h and then treated with bortezomib at indicated concentrations.
(e) Scheme for functional screening to quantitate the miR effect on proteasome activity in human embryonic kidney (HEK) cells stably
transfected with GFPu. (f) Bortezomib effect on GFPu accumulation. HEK cells were treated with bortezomib for 16 h and imaged using confocal
microscopy. (g) Quantitation of the bortezomib effect on HEK cells. Relative ﬂuorescence was determined using the ImageJ image processing
and analysis software. (h) Effect of bortezomib on ﬂuorescence in HEK cells transfected with control or miR replacements. Cells were transfected
with indicated miRs, cultured for 48 h and treated with bortezomib. (i) Effect of bortezomib on ﬂuorescence in HEK cells transfected with
scrambled control or miR antagomirs. Cells were transfected with indicated miRs, cultured for 48 h and treated with bortezomib for 16 h.
(j) Quantitation of miR replacement effect on cell ﬂuorescence after bortezomib treatment. Relative ﬂuorescence was determined using the
ImageJ processing and analysis software. (k) Quantitation of antagomir effect on ﬂuorescence after bortezomib treatment. Relative ﬂuorescence
was determined using the ImageJ image processing and analysis software. ⋆ denotes members of the miR-29b family.
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promoted myeloma viability in the presence of bortezomib
(Figures 1c and d).
Numerous mechanisms have been proposed to explain the
molecular basis for bortezomib resistance; however, a limited
number of these directly address the functional or structural
properties of the proteasome. Whereas biochemical assays are
useful in rapidly assessing the functional status of the proteasome,
such assays do not incorporate the intricacy of substrate passage
through the many physiologically relevant steps within the UPS.
We reasoned that a live-cell system that employed a short-lived
reporter offered a more satisfactory means to assess miR effects
on the UPS. Proteasome activity was monitored by the
ﬂuorescence emitted from cells that expressed GFPu (Figure 1e).
After MG132 treatment, GFPu is co-immunoprecipitated with Ub
and pulse-chase experiments indicated that the GFPu half-life is
signiﬁcantly increased upon proteasome inhibition.20 Human
embryonic kidney cells were transfected with GFPu, treated with
bortezomib and ﬂuorescence was measured with confocal
imaging. After bortezomib treatment, we saw an approximately
sixfold increase in ﬂuorescence compared with cells treated with
vehicle alone (Figures 1f and g). GFPu-expressing human
embryonic kidney cells were then transfected with individual
replacements or antagomirs, treated with bortezomib and
ﬂuorescence was measured (Figures 1h and i). In contrast to
control-transfected cells, ﬂuorescence from cells transfected with
miR replacements 1246, 1290, 1915, 3185 and 4271 did not
signiﬁcantly increase after bortezomib treatment to suggest that
the miRs promoted ﬂux through the UPS and GFPu degradation
even in the presence of bortezomib (Figure 1j). Fluorescence from
cells transfected with antagomirs designed to reduce the
endogenous levels of miR-21, 27a, 29a, 29b, 29c, 92a and 192
did not increase with bortezomib (Figure 1k).
Figure 2. MiR-29b targets PSME4. (a) Nucleotide sequence of the mature pre-miRs that are processed to generate miR-29a and 29b1 from
chromosome 7 and miR-29b2 and 29c from Chromosome 1. The putative hexanucleotide NLS in each member is shown in blue. (b) RT-PCR
quantitation of miR-29 in parental and PI-resistant cells. (c) MiR-29b complementarity to PSME4 that encodes the proteasome activator PA200.
(d) Luciferase readout demonstrating that miR-29 family members speciﬁcally target the PSME4 3′-UTR. MiRNAs reduced in cells resistant to PIs
were identiﬁed. On the basis of predictive algorithms, putative binding to sites within the 3′-UTR of PSME4 were determined. MiR 3′-UTR target
clones and luciferase-based readout. The PSME4 3′-UTR was inserted into pEZ-MT01, a dual ﬁreﬂy/renilla dual luciferase reporter mammalian
expression vector (GeneCopoeia, Rockville, MD, USA). Either the PSME4 3′-UTR-speciﬁc or empty vector control (pEZ-MT01 alone) were then
transfected in HEK-293T target cells. MiR 3′-UTR target clones were used for miR target identiﬁcation and functional validation of the
predicted targets or to study the regulatory effect of miR on target gene(s). The PSME4 3′-UTR sequence was inserted downstream of the
ﬁreﬂy luciferase included on miTarget 3′-UTR target clones, driven by the SV40 enhancer. Downstream of the miR 3′-UTR target reporter is the
renilla luciferase reporter driven by a cytomegalovirus (CMV) promoter, which is also cloned into pEZX-MT01 that serves as the internal
control. HEK293 cells were plated on a six-well plate, transfected with 1 μg of PSME4 3′-UTR miR target sequence expression clone in pEZX-
MT01 vector with Luc and 20 nM of chemically synthesized miRs. Cells were transferred to a 96-well plate 18 h after transfection and cultured
for 24 h. Both ﬁreﬂy luciferase and Renilla luciferase activities were measured and data were recorded on BMG Labtech FLUOstar OPTIMA.
Fireﬂy luciferase activity was then normalized with the renilla luciferase activities in the same well. (e) Northern blot analysis to determine the
effect of deletion of the miR-29b NLS on subcellular localization. 293T cells transfected with control or the experimental miR replacements
were harvested, lysates were prepared and separated into nuclear and cytoplasmic fractions. The efﬁciency of transfection was veriﬁed by
subjecting the plasmids to northern blot analysis and probing with either tRNAlys (cytoplasmic fraction) or U6 small nuclear RNA (snRNA)
(nuclear fraction). Oligonucleotide probes were 5′ end-labeled with digoxigenin (DIG). ⋆ denotes that miR-29b was not signiﬁcantly detected.
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Genomic and functional screening indicated that miR-29a and
29b-1 (chromosome 7q32.3) and miR-29b2 and 29c (chromosome
1q32) were reduced in bortezomib-resistant cells (Figure 2a).
MiR-29a/b/c share extensive homology within the 3′-untran-
scribed region (UTR) seed sequence that binds target mRNAs.
Clinical success of bortezomib has led to the development of
second-generation PIs, and RPMI8226 cells resistant to carﬁlzomib
or ixazomib were then generated through successive drug
exposure. RT-polymerase chain reaction (RT-PCR) indicated that
miR-29a, 29b and 29c were each reduced in bortezomib-,
carﬁlzomib- and ixazomib-resistant cells compared with the
parental cells (Figure 2b). Predictive algorithms and database
analyses identiﬁed mRNAs potentially targeted by miR-29b. On
the basis of sequence complementarity and calculated miRSVR
scores, 6995 putative mRNA targets of miR-29b were detected. We
focused on UPS components as putative miR-29 targets, as it
appeared reasonable to be used as a direct mechanism to
promote PI resistance. Comparison of miRSVR scores for miR-29b
targets revealed that PSME4, which encodes the proteasome
activator PA200, was − 1.35 and ranked PSME4 in the top 1% (73rd
out of 6995) as a miR-29 target. Similarly, ~ 1100 human miRs were
rank ordered based upon their summed miRSVR scores as putative
miRs that targeted PSME4. On the basis of predictive miRSVR
scores, miR-29b and 29c ranked 5th and 6th highest, respectively,
as miRs most likely to target PSME4. Moreover, the miRSVR score
for PSME4 was more signiﬁcant than that of DNMT3a (−1.22) and
DNMT3b (−1.21), previously been reported as miR-29b targets.21
The PSME4 3′-UTR is homologous to the miR-29b seed sequence
(Figure 2c) and the miR-29b replacement effect on PSME4
expression was determined. A vector that encoded the PSME4
3′-UTR controlled by the renilla luciferase reporter and ﬁreﬂy
luciferase normalization genes was transfected into 293T cells.
MiR-29b and 29c replacements signiﬁcantly reduced luciferase-
generated ﬂuorescent readout from the reporter by 440%
relative to the control vector. PSME4 expression was highly
sensitive to miR-29b (Figure 2d) and supported the ﬁndings that
miR-29b modulated proteasome activity (Figures 1c and d). MiRs
function through negative regulation of gene expression, in part,
through partial sequence complementarity to target mRNAs.
However, miRs may also contain additional sequence elements
that control their functional activity, post-transcriptional behavior
and/or subcellular localization.22 As miR-29b contains a distinct
hexanucleotide 3′ motif that acts as a transferable NLS to direct
nuclear enrichment, miR-29a/b/c variants were synthesized
lacking the NLS (Figure 2a). NLS deletion from miR-29a/b/c
enhanced their repression of PSME4 (Figure 2d). Therefore, we
reasoned that deletion of the miR-29bΔNLS would increase
cytoplasmic enrichment. 293T cells were transfected with
lentivirus that expressed control miR, miR-29b or miR-29bΔNLS,
lysates prepared and nuclear and cytoplasmic fractions isolated.
Northern blot analysis indicated that NLS deletion from miR-29b
enriched cytoplasmic localization (Figure 2e).
MiR-29a, 29b and 29c replacements were transfected into
myeloma cells and the effect on viability measured in RT
(Figure 3a). The miR replacements reduced growth alone or
combined with bortezomib. Deletion of the NLS from the miR-29a/
b/c replacements further enhanced the inhibitory effect on
growth in the presence of PIs (Figure 3b). To corroborate the
antiproliferative effect of synthetically engineered miR-29 replace-
ments, we employed expression vectors to generate miR-29a, -b
or -c in myeloma cells. RPMI8226 cells were transduced with
lentiviral vectors that expressed miR-29a, 29b or 29c and growth
was measured in RT (Figure 3c). Similar to the synthetically
engineered miR replacements, vector-based expression of
miR-29b also reduced cell growth. We next investigated the
miR-29b effect on the NFκB pathway, activated in tumor cells
upon stress or chemotherapy to promote survival. As the level of
miR-29b was reduced in PI-resistant cells, a synthetically
engineered miR-29b antagomir was employed to inhibit endo-
genous miR-29b. Transfection of the miR-29b antagomir increased
NFκB activity, whereas miR-29b and miR-29bΔNLS replacements
reduced NFκB activity (Figure 3d). MiR-29b antagomirs also
increased BrDU incorporation, whereas miR-29b replacements
reduced incorporation (Figure 3e). MiR-29b replacement also
reduced colony formation (Figure 3f) and increased the number of
annexin-positive cells after PI treatment (Figure 3g). MiR-29b
replacements also reduced the proliferation of other myeloma cell
lines as well as cells from other malignant and nonmalignant B-cell
types (Supplementary Figure 2).
PA200 functions in a variety of processes including proteasome
assembly,23 DNA repair,24 genomic stability,25 proteasome
inhibition,26 spermatogenesis27 and mitochondrial checkpoint
regulation28 and stimulates the peptide-hydrolyzing activity of
proteasomes. We reasoned that miR-29b reduction should
reciprocally increase PA200 levels and enhance peptide-
hydrolyzing activity of the proteasome. Lysates from PI-resistant
cells were probed with western blot to indicate that PA200 levels
were increased in PI-resistant cells compared with parental cells
(Figure 4a). We hypothesized that synthetically engineered miR
replacements could be exploited to inhibit PSME4 and lead to
reduced PA200 levels, proteasome inhibition and cell death.
Parental and PI-resistant cells were transfected with control miR,
miR-29b replacements or miR-29bΔNLS replacements, cultured in
the presence or absence of bortezomib and viability was
determined (Figure 4b). PI-resistant cells transfected with
miR-29b or miR-29bΔNLS replacements were less viable than
cells transfected with control miR. In addition, transfection of PI-
resistant cells with miR-29b or miR-29bΔNLS replacements
enhanced their sensitivity to bortezomib. Hence, miR-29b
replacement induced cytotoxicity either alone or in combination
with bortezomib. We next determined the effect of miR-29b
replacement on myeloma patient bone marrow-derived CD138+
cells. The cells were transfected with control miR, miR-29b or
miR-29bΔNLS replacements, cultured for 24 h and treated with
bortezomib. Bortezomib reduced the viability of patient CD138+
cells and the effect was increased after transfection of miR-29b or
miR-29bΔNLS replacements (Figure 4c). RT-PCR demonstrated that
miR-29b was reduced in PI-resistant cells and that miR-29b was
reduced in patient CD138+ cells relative to CD138+ cells from
healthy individuals (Figure 4d).
Whereas efﬁcient substrate recognition by the proteasomal
requires poly-Ub chain attachment to the targeted protein,29
proteasomes also have the capacity to recognize and degrade
substrates that do not require ubiquitination.30 These include the
cyclin-dependent kinase inhibitor p21, the transcriptional activator
Rpn4 and ornithine decarboxylase (ODC).31 To address the role of
miR-29b on Ub-independent proteasome activity, PA200 null
(PA200Δ/Δ) lymphocytes were generated through Cre-loxP-
mediated recombination.27 PA200+/+ and PA200Δ/Δ lymphocytes
were then transfected with a vector that expressed GFP-ODCwt.
PA200+/+ and PA200Δ/Δ cells that expressed GFP-ODCwt were
treated with cycloheximide and lysates were probed. Western blot
analysis indicated that GFP-ODCwt was degraded much more
rapidly in PA200+/+ cells than in PA200Δ/Δ cells (Figure 5a). The
half-life of GFP-ODCwt in PA200+/+ cells was ~ 15min but was
greater than 2 h in the PA200Δ/Δ cells.31 PA200+/+ and PA200Δ/Δ
cells were transfected with miR-29b replacements to determine
whether the miR-29b effect on proteasomes required PA200.
Transfection of PA200Δ/Δ cells with control miR or miR-29b
replacements did not change the GFP-ODCwt steady-state level
(Figure 5b). However, transfection of miR-29b replacements into
PA200+/+ cells signiﬁcantly increased the steady-state level of GFP-
ODCwt, consistent with miR-29b replacement inhibiting PSME4,
reducing PA200 and decreasing proteasome activity. The 20S
proteasome core particle (CP) and the 26S proteasome (20S CP
capped by 19S regulatory particles, RP-CP-RP) have been shown to
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associate with PA200 (refs 32,33). The 19S RP is responsible for
selecting ubiquitinated proteins for degradation by the 20S CP. To
investigate the impact of miR-29b replacement on proteasomes,
myeloma cells were transfected with control miR or miR-29b
replacements and either untreated or bortezomib treated.
Lysates were fractionated, separated by nondenaturing gel
electrophoresis and proteasome activity determined in situ upon
incubation of the gel with the chymotrypsin-like substrate Suc-
LLVY-MCA (Figure 5c). The in situ assay detected puriﬁed 26S (lane
1) and 20S proteasomes (lane 2). Control miR-transfected
myeloma cells displayed two major peptide-hydrolyzing activities
that migrated consistent with the 26S and 20S proteasome forms.
However, these cells also contained at least three other peptide-
hydrolyzing activities that migrated between the 26S and 20S
proteasomes (lane 3, indicated by *). These activities may
represent 20S CP hybrid proteasomes associated with a single
RP and/or PA200. Proteasomes isolated from bortezomib-treated
cells displayed reduced peptide-hydrolyzing activity independent
of transfection with either control or miR-29b replacements
(lanes 4, 6). Proteasomes from cells transfected with miR-29b
replacements displayed reduced 26S proteasome peptide-
hydrolyzing activity and lacked the three peptide-hydrolyzing
activities that migrated between 26S and 20S proteasomes
(lane 5). Thus, miR-29b replacement reduced the relative amount
of peptide-hydrolyzing activity associated with 26S proteasomes.
The proteasome hybrid forms that migrated below the 26S and
Figure 3. MiR-29b replacement effect on myeloma viability. (a) RT determination of miR-29 replacement on myeloma conﬂuency. Cells were
transfected with miRs (20 nM) and conﬂuency determined in RT. (b) RT determination of miR-29 replacement effect on proliferation in the
presence of bortezomib. Cells were transfected with indicated miRs (20 nM) and conﬂuency determined in RT over 36 h at the indicated
bortezomib concentrations. (c) Vector-based miR-29 replacement effect on myeloma cells in the presence of bortezomib. Cells were
transfected with lentiviral vectors, selected with puromycin and the effect on viability was determined in the absence or presence of
bortezomib at the indicated concentrations. (d) miR-29b effect on NFκB activity in the presence or absence of tumor necrosis factor-α.
(e) miR-29b antagomir effect on proliferation. (f) miR-29 replacement effect on colony formation in methylcellulose (MC). MM cells were
transfected with indicated miR replacements and the number of colonies counted after 7 days. Shown is the average of triplicate
measurements. (g) MiR-29 replacement effect on the generation of annexin-positive cells in the presence of bortezomib. Myeloma cells were
transfected with indicated miR replacements and the percentage of annexin-positive cells determined with ﬂow cytometry. Cells transfected
with control miR were normalized to 100% and the effect of each miR was determined.
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above the 20S proteasomes were also decreased after transfection
of miR-29b replacements. The proteasome β5 catalytic subunit
(PSMB5) is a component of both 26S and 20S proteasomes.
Therefore, western blot analysis with the PSMB5 antibody was
used to determine the effect of miR-29b replacements on
the relative amount of 26S and 20S proteasomes (Figure 5d).
Lysates were prepared, fractionated, proteins separated by
nondenaturing PAGE and probed by western blot. Proteasomes
from control miR-transfected cells indicated PSMB5-immuno-
reactive bands that migrated similar to puriﬁed 26S and 20S
proteasomes. Control miR-transfected cells also contained PSMB5-
immunoreactive bands that migrated between the 26S and 20S
proteasomes. However, proteasomes from cells transfected with
miR-29 replacements demonstrated reduced PSMB5 staining at
migration distances expected for the 26S proteasomes and
proteasome that migrated between the 26S and 20S. Western
blot analysis also indicated that PA200 association with 26S
proteasomes was reduced in cells transfected with miR-29b
replacements compared with control-transfected cells. Thus,
miR-29b replacements reduced the relative amount of 26S
proteasome activity and reduced the amount of PA200 associated
with proteasomes.
As miR-29b replacements inhibited proteasome activity, we
determined whether miR replacement, similar to bortezomib,
induced the aggresome+autophagy pathway. Confocal microscopy
indicated that bortezomib treatment of control or miR-29b-
transfected cells promoted Ub colocalization with the aggresome
component histone deactylase 6 (HDAC6), similar to the effect of
bortezomib seen in prior studies.34,35 p62/SQSTM1 is a Ub-binding
protein and aggresome component that localizes with protein
aggregates and bortezomib treatment increased p62 staining
throughout the cytoplasm of both control and miR-29b-
transfected cells. Protein aggregates within the cytoplasm are
coalesced by microtubule-dependent retrograde transport to
perinuclear deposition sites, referred to as aggresomes. Aggre-
somes are initially dispersed throughout the cytoplasm and
subsequently travel on microtubules to the microtubule organiz-
ing center region, where they remain as distinct particulate
structures entangled with collapsed intermediate ﬁlaments. We
employed a novel, excitable red-ﬂuorescent dye that speciﬁcally
detects aggresomes. After bortezomib treatment, perinuclear
aggresomes were readily detected in control-transfected cells
but not in the miR-29b-transfected cells. The results suggest that
miR-29b replacement enhances bortezomib-induced accumula-
tion of protein aggregates but that these aggregates are not
coalesced into perinuclear aggresomes. Bortezomib treatment
also did not increase autophagosomes in the miR-29b-transfected
cells as was seen in control-transfected cells.
Protein aggregation observed with miR-29b and bortezomib
could result from inhibition of autophagy or lysosomal degradation
Figure 4. MiR-29b replacement effect on myeloma patient tumor samples. (a) Western blot of PA200 levels in parental and PI-resistant cells.
Lysates from parental and PI-resistant cells were probed with an antibody speciﬁc to PA200. (b) Cytotoxic effect of control or miR-29b and
miR-29bΔNLS on parental and PI-resistant cells. Myeloma cells resistant to the PIs bortezomib or carﬁlzomib were transfected with the
indicated miR replacements (20 nM) and the effect on viability determined using the XTT assay. (c) Effect of control or miR-29b on myeloma
patient tumor cells. CD138+ PCs from bone marrow (BM; ConversantBio, Huntsville, AL, USA) were isolated using microbead-positive selection
(Miltenyi Biotec, Auburn, CA, USA). Samples were made 485% pure by ﬂow cytometry using an anti-allo APC-labeled CD138+ antibody.
CD138+ plasma cells were transfected with indicated miR replacements (20 nM) and the effect on cell viability determined using the XTT assay
at 48 h. (d) RT-PCR of miR-29b in plasma cells isolated from BM of healthy individuals and MM patients. ⋆ denotes that the product was not
detectable by RT-PCR.
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of aggresomes late in the autophagy pathway. To distinguish
between these possibilities, we investigated the effect of miR-29b
replacements with or without bortezomib on LC3BII accumulation.
Activation of autophagy results in LC3B lipidation that can be
detected by faster migration on SDS-PAGE (as LC3BII). Western
blot analysis indicated that both p62 and LC3BII increased when
cells were treated with miR-29b and bortezomib (Figure 6b).
However, because both p62 and LC3BII are degraded by
autophagy, increased steady-state levels could result from either
the activation or inhibition of autophagy. To discriminate between
these possibilities, cells were treated with chloroquine during the
last 30 min of incubation to suppress lysosomal-dependent
protein degradation in autophagosomes. LC3BII accumulation
occurred independent of bortezomib or miR-29b as well as in the
presence or absence of chloroquine. As the increase in LCB3II
occurred in untreated and treated cells, these data suggest that
autophagy is active in these cells and unaffected by bortezomib,
miR-29b or the combination. The results also suggested that
miR-29b synergized with bortezomib to induce Ub-aggregate
accumulation that was uncoupled from the formation of peri-
nuclear aggresomes and autophagosomes. As miR-29b targeted
PSME4, which encodes PA200, we determined the effect of PA200
knockout on aggresome formation (Figure 6c). Upon bortezomib
treatment, we detected aggresomes and autophagosomes in
PA200+/+ cells but signiﬁcantly reduced levels in PA200− /− cells
(Figure 6c).
To determine the in vivo effect of miR-29b replacement,
lentiviral vectors that expressed control, miR-29b or miR-29bΔNLS
were transfected into RPMI8226 cells that were then injected into
the ﬂanks of NOD.CB17-Prkdcscid/J mice (Figure 7a). Mice injected
with control miR-transduced cells developed tumors earlier than
the other groups, and tumor volumes increased more than those
generated using cells transduced with miR-29b or miR-29bΔNLS.
Survival of mice injected with cells transduced with miR-29b or
miR-29bΔNLS was also signiﬁcantly longer compared with mice
injected with control cells (Figure 7b). Imaging indicated that the
ﬂanks of mice injected with cells expressing control miR emitted
greater ﬂuorescence than ﬂanks of mice injected with cells
expressing miR-29b or miR-29bΔNLS (Figure 7c).
DISCUSSION
The UPS is an attractive therapeutic target because of its stringent
regulation of pro-survival and anti-apoptotic regulators. Bortezo-
mib represents a remarkable bench-to-bedside success but
sustained response is hindered by drug resistance. We identiﬁed
miRs deregulated in PI-resistant cells and establish a compelling
link between miRs and PI resistance.34–36 A diversity of mechan-
isms has been proposed to explain how malignant cells escape
PIs, including alterations in the proteasome itself.37,38 For example,
in myelomonocytic cell lines, mutations in the proteasome
catalytic subunit PSMB5 impair bortezomib binding and PSMB5
is upregulated following bortezomib exposure. PSMB5 induction
wanes with time off-therapy, but reappears rapidly after drug re-
exposure to highlight the susceptibility of proteasomes to genetic
modiﬁcations under selection pressure, as may occur in patients
with continued treatment. Our results provide a proof-of-principle
to demonstrate that miRs offer potential as novel therapeutic
Figure 5. MiR-29b replacement affects PA200 association with proteasomes. (a) Effect of PA200 expression on GFP-ODCwt half-life. PA200+/+
and PA200Δ/Δ cells were transfected with GFP-ODCwt, treated with cycloheximide and lysates were prepared at indicated time points. Lysates
were separated with SDS-PAGE and probed using a GFP-speciﬁc antibody. (b) Effect of miR-29b on the steady-state level of GFP-ODCwt in
PA200Δ/Δ and PA200Δ/Δ cells. Lymphocytes were transfected with control miR or miR-29b replacements, expanded and treated with
bortezomib. Lysates were separated with SDS-PAGE and probed using a GFP-speciﬁc antibody. (c) MiR-29b replacement effect on proteasome
activity. Puriﬁed human proteasomes (20S or 26S) or proteasomes isolated from myeloma cells were electrophoresed on Bio-Rad (Hercules,
CA, USA) Criterion XT 4–20% Tris-Borate EDTA (TBE) gels run in TBE buffer (pH 8.3) at 4 °C and 25 V for 24 h. Nondenaturing 4% gel
electrophoresis separated proteasomes isolated from the myeloma cells after transfection with either control miR or miR-29b. Chymotrypsin-
like peptide hydrolyzing activity of proteasomes was determined by incubating the gel with Suc-LLVY-MCA. (d) MiR-29b replacement effect on
proteasomes. Lysates from myeloma cells transfected with control miR or miR-29b replacements were separated by nondenaturing 4% PAGE,
transferred to nitrocellulose and probed with western blot using an antibody to PSMB5 to determine the miR effect on the relative amount of
the different proteasome forms. Puriﬁed 26S and 20S proteasomes (2 μg) were loaded separately as controls. Lysates from myeloma cells
transfected with control miR or miR-29b replacements were separated by nondenaturing 4% PAGE, transferred to nitrocellulose and also
probed using an antibody to PA200 to determine the miR effect on PA200 association with proteasomes.
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Figure 6. MiR-29b replacement affects on aggresome and autophagy formation. (a) Immunoﬂuorescent colocalization of Ub, p62 and HDA6 in
RPMI8226 cells. Cells were transfected with control miR or miR-29b replacements and treated with bortezomib for 16 h. Images were
visualized using a Zeiss LSM 170 confocal microscope (Zeiss Microscopy) with Axio Observer Z1. Aggresomes were visualized using the Enzo
Proteostat aggresome detection kit (Enzo Life Sciences, Farmingdale, NY, USA). Autophagosomes were detected using the Cyto-ID autophagy
detection kit (Enzo Life Sciences) according to the manufacturer’s instructions. (b) Western blot of p62 and LC3B in RPMI8226 cells transfected
with either control miR or miR-29b and treated with bortezomib. Cells were treated with chloroquine for the ﬁnal 30min of incubation to
allow for autophagsome accumulation. (c) Aggresome and autophagosome formation in PA200+/+ and PA200− /− cells. Cells were treated with
bortezomib and aggresomes and autophagosomes detected using the Enzo detection kits.
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agents to inhibit proteasomes and provide an alternative strategy
to disrupt the UPS (Figure 8). Proﬁling of patient tumor cells to
quantitate miR levels may provide useful information to predict
the response to bortezomib. In addition, we envision the
development of a panel of miRs that correlate with drug response
as a signature for use in clinical practice to identify those patients
less likely to respond to bortezomib-based therapy. These patients
could then be treated upfront with more aggressive therapies.
Whereas it is reasonable to assume that miR-29b targets
multiple mRNAs, a number of observations are consistent with a
direct effect on PSME4. MiR-29b antagomirs increased proteaso-
mal degradation of GFPu and miR-29b replacements inhibited
PSME4 expression, reduced PA200 levels and decreased PA200
association with proteasomes. Proteasomes isolated from cells
transfected with miR-29b replacements displayed reduced pepti-
dase activity. PA200-CP complexes were observed under stress
conditions to also suggest that PA200 increases proteasome
activity.33,39 Substrates access the central chamber of the
proteasome through narrow gates deﬁned by the outer α-rings
of the 20S CP. In the absence of activators, these gates are closed
by the 20S-α subunits that forge these rings to repress proteolysis
rates.33 Three-dimensional molecular structures determined with
X-ray crystallography of CP-bound Blm10 (the yeast PA200
homolog) have provided a model for gate-opening and
activation.33 PA200/Blm10 inserts into a dedicated pocket in the
outer ring of the CP surface to induce and stabilize a partially open
gate conformation. MiR-29b reduction also enhanced Ub-
independent degradation to support the concept that short-
lived proto-oncogenes, onco-suppressive proteins and core
histones are degraded through Ub-independent, proteasome-
dependent mechanisms.40 PA200 may direct the degradation of
speciﬁc protein classes or direct localized proteasome
degradation.
We demonstrate that miR-29b replacements combined with
bortezomib enhance the accumulation of protein aggregates but
that aggresome and autophagosome formations were impaired
and that uncoupling toxic protein accumulation from the
aggresome+autophagy pathways enhances the cytotoxic effect
of bortezomib. HDAC inhibitors combined with bortezomib also
inhibit aggresome formation and increase the apoptotic effect of
Figure 7. In vivo effect of miR-29b replacements on myeloma xenotransplants. (a) Effect of miR-29b and miR-29bΔNLS on tumor volume of
myeloma xenotransplants.The TRIPZ inducible lentiviral system was used to express control or miR-29b in MM cells before their subcutaneous
xenotransplantation into NOD/SCID female mice. The TRIPZ-inducible system employed a doxycycline-inducible promoter. The TRE, modiﬁed
from its natural state to consist of a string of operators fused to the CMV minimal promoter, reduced the basal expression and tighter binding
to the second component, the transactivator. The pTRIPZ transactivator, known as the reverse tetracycline transactivator, binds and activates
expression from TRE promoters in the presence of doxycycline. Mutations within the rtTA increase sensitivity to doxycycline by 25-fold over
the initial rtTA without increasing background.51 Cells (3 × 106) transduced with lentivirus expressing either control, miR-29b or miR-29bΔNLS
were subcutaneously injected into the ﬂanks of 5-week-old, female NOD.CB17-Prkdcscid/J mice, with ﬁve mice/group. After detection of
measurable (450mm3) tumors, mice were started on an alfalfa-free diet supplemented with doxycycline (Dox) to enhance pTRIZ promoter
expression. Tumor volume was determined by external measurement using electronic calipers. Each group contained ﬁve mice and the mice
were injected in each ﬂank. Shown is the average of replicate measurements from the ﬁve mice in each group. Subcutaneous tumor volume
was determined by obtaining external measurements with a digital caliper using the modiﬁed ellipsoidal formula: tumor volume=½
(length ×width2). (b) Effect of miR-29b and miR-29bΔNLS on overall survival. The in vivo efﬁcacy of lentiviral-delivered miR-29b replacements
on the viability of NOD/SCID mice was determined over 10 weeks after subcutaneous injection. Overall survival of the mice that were injected
with MM cells transfected with either the scrambled or the experimental miRs. (c) Effect of miR-29b and miR-29bΔNLS on tumor size by
ﬂuorescence imaging of TurboRFP-expressing cells implanted subcutaneously on the ﬂanks of NOD.CB17-Prkdcscid/J mice. Shown is a
representative mouse from each group of ﬁve mice. Imaging was completed using the in vivo MultiSpectral FX Pro (Bruker Biospin, Billerica,
MA, USA) in the Vontz Core Imaging Laboratory. TurboRFP ﬂuorescence was captured with the IS400MM camera with 550 nm excitation ﬁlter
and 600 nm emission ﬁlter. Images were acquired for 10 s with 4 × 4 binning and data were processed with the Carestream software
(Rochester, NY, USA).
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the drug.41–43 Likewise, the farnesyl transferase inhibitor lonafar-
nib (tipifarnib) synergizes with bortezomib to enhance the
accumulation of ubiquitinated proteins. The efﬁcient packaging
of proteins into aggresomes is clearly important in the cells’ ability
to manage misfolded proteins but must be coupled with efﬁcient
delivery of the aggresome to autophagosomes.44 The therapeutic
use of miRs has gained much attention because their mechanisms
of action are consistent with the current approach to treat cancer
as a pathway-based disease. MiRs are master regulators of the
genome that modulate hundreds of genes and control multiple
essential cellular pathways. Thus, miR-based therapeutics are
highly applicable to a molecularly heterogeneous disease with
distinct genetic subtypes, for example, MM and B-cell
disorders.45–47 A number of miRs, including miR-29b, show a loss
of function in a broad range of cancer types, indicating that they
have a central role in regulating tumor suppression.48,49 Correct-
ing these deﬁciencies by miR replacement results in the activation
of pro-apoptotic pathways. Since the groundbreaking discovery
that miRs were aberrantly expressed in cancers, signiﬁcant
progress has advanced the clinical development as diagnostics
and therapeutics.50
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